Teva Scores against Novartis, GlaxoSmithKline

Teva Scores against Novartis, GlaxoSmithKline

Teva is free to resume sales of its generic famciclovir (Novartis’ Famvir), following the US Court of Appeals for the Federal Circuit’s denial of Novartis’ emergency motion for an injunction against Teva. Here’s Teva’s press release (9/28).

Teva may also market, in the US, its generic versions of GlaxoSmithKline's Avandia (rosiglitazone maleate), Avandamet (rosiglitazone maleate/metformin HCl), and Avandaryl (rosiglitazone maleate/glimepiride) oral tablets, come 2012. Teva (9/27)

And that timing is seemingly good. As reported by The Boston Globe (9/27), Lahey Clinic researchers concluded from their study of Actos and Avandia that while drugs from that class increase the relative risk of heart failure (a previously known risk factor) in people who have type 2 diabetes, they do not raise the risk of cardiovascular death. An earlier review (6/07), by Steven E. Nissen of the Cleveland Clinic, found a significant increase in the risk of heart attack for people taking Avandia and a borderline-significant risk of cardiovascular death. The lead investigator for the Lahey Clinic study said the data his group examined were more robust than the results analyzed by Nissen.

Click here to log in.


Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

Privacy Analytics
How to Safeguard for PHI
Sponsored by Privacy Analytics

5 Ways to Manage the Rising Costs of Benefits for small and medium-sized businesses
Sponsored by TriNet

Data Virtualization: Agile Data Solutions for Life Sciences
Sponsored by Denodo

Life Science Webcasts & Podcasts

medidata_podcast_Sites and Sponsors: Mending Bridges over Troubled Waters  
Sites and Sponsors: Mending Bridges over Troubled Waters
Sponsored by Medidata Solutions Worldwide

This podcast brings together two industry leaders to focus on the issues that divide sponsors and sites. On the one hand sites and sponsors unite in advancing better health care through a common passion for developing better drugs. Yet some issues divide them and bridges need to be built or mended to advance the highest levels of cooperation, coordination and success in clinical trials. Listen as the key issues are debated from the site and the sponsor side and new methods and technology are advanced that offer near-term and lasting solutions.

• Common ground in reaching agreement on a budget

• Improving the pace of agreement on budgets and contracts

• Processes for payment to sites on a timely basis

Listen Now  

More Podcasts

Job Openings

For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 ,